newsfilter
← Latest News
GlobeNewswire·

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase